BusinessCloud Email Newsletter

News - MedTech

Oxford BioMedica shares fall 15% in one day

Shares in Oxford BioMedica fell 15% today despite a recent positive half-year trading update. In ...

UK’s Scan.com raises $220m to dominate US market

Scan.com has closed $220 million (£162m) in combined equity and debt financing after doubling reven...

Meet Leeds spinout ‘reinventing the injection’

For Henry Dunne, the idea that would become Microneedle Solutions (MNS) started while he was studyin...

New CFO at crisis firm SkinBioTherapeutics

A new interim CFO has been appointed at SkinBioTherapeutics plc following the departure of the figur...

$125m financing to see Macclesfield’s Redx list on Nasdaq

Redx Pharma, a drug discovery and development company, has sealed a long-term funding deal that will...

Oxford Nanopore exec named CEO at Oxford BioDynamics

A former key executive at Oxford Nanopore Technologies has been named CEO at fellow biotechnology fi...

TRIMTECH Therapeutics seed round tops £35m

TRIMTECH Therapeutics’ seed round has topped £35 million. The Cambridge biotechnology company ...

Nuclear fusion pioneer raises £23m to battle cancer

Astral Systems - a deep-tech firm pioneering a new type of nuclear fusion technology - has secured Â...

Physiomics wins multiple contracts after boardroom coup

Physiomics plc has won multiple contracts following a boardroom coup. Physiomics is a mathematica...

Sir Demis Hassabis’s Isomorphic Labs raises £1.6bn

Isomorphic Labs, an AI-first drug design and development company founded by DeepMind founder Sir Dem...

Physiomics looks to future after entire board ousted

The new corporate leadership team at Physiomics plc has painted a positive picture after ousting the...

Why ‘unique’ HealthTech is at cutting edge of mental health support

One of the challenges facing UK universities is how to commercialise the world-leading innovations t...

Subscribe to our newsletter

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.